|
|
帕金森病的初始药物治疗策略
|
Abstract:
帕金森病(Parkinson’s Disease, PD)是最常见的神经变性运动障碍，目前药物治疗仍是目前临床上控制和缓解其症状的主要方法。本文综述主要梳理帕金森病患者起始用药管理及相关不良反应和疗效，以期为临床医生提供合理的药物选择，制定精准的治疗方案，旨为更好地医治患者，提高生存质量。
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting millions of adults worldwide. This review mainly reviews the initial medication management and related adverse reactions and efficacy of patients with Parkinson’s disease, in order to provide clinicians with reasonable drug choices and formulate precise treatment plans, with the aim of better treating patients and improving the quality of life.
| [1] | Fox, S.H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R.M.A., Seppi, K., et al. (2018) International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson’s Disease. Movement Disorders, 33, 1248-1266. https://doi.org/10.1002/mds.27372 |
| [2] | Pringsheim, T., Day, G.S., Smith, D.B., Rae-Grant, A., Licking, N., Armstrong, M.J., et al. (2021) Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology, 97, 942-957. https://doi.org/10.1212/wnl.0000000000012868 |
| [3] | Connolly, B.S. and Lang, A.E. (2014) Pharmacological Treatment of Parkinson Disease. Journal of the American Medical Association, 311, Article 1670. https://doi.org/10.1001/jama.2014.3654 |
| [4] | Rogers, G., Davies, D., Pink, J. and Cooper, P. (2017) Parkinson’s Disease: Summary of Updated NICE Guidance. British Medical Journal, 358, j1951. https://doi.org/10.1136/bmj.j1951 |
| [5] | Grimes, D., Fitzpatrick, M., Gordon, J., Miyasaki, J., Fon, E.A., Schlossmacher, M., et al. (2019) Canadian Guideline for Parkinson Disease. Canadian Medical Association Journal, 191, E989-E1004. https://doi.org/10.1503/cmaj.181504 |
| [6] | Calabresi, P., Filippo, M.D., Ghiglieri, V., Tambasco, N. and Picconi, B. (2010) Levodopa-Induced Dyskinesias in Patients with Parkinson’s Disease: Filling the Bench-to-Bedside Gap. The Lancet Neurology, 9, 1106-1117. https://doi.org/10.1016/s1474-4422(10)70218-0 |
| [7] | Aquino, C.C. and Fox, S.H. (2014) Clinical Spectrum of Levodopa-Induced Complications. Movement Disorders, 30, 80-89. https://doi.org/10.1002/mds.26125 |
| [8] | Olanow, C.W., Watts, R.L. and Koller, W.C. (2001) An Algorithm (Decision Tree) for the Management of Parkinson’s Disease. Neurology, 56, S1-S88. https://doi.org/10.1212/wnl.56.suppl_5.s1 |
| [9] | Fereshtehnejad, S., Shafieesabet, M., Farhadi, F., Hadizadeh, H., Rahmani, A., Naderi, N., et al. (2015) Heterogeneous Determinants of Quality of Life in Different Phenotypes of Parkinson’s Disease. PLOS ONE, 10, e0137081. https://doi.org/10.1371/journal.pone.0137081 |
| [10] | Fahn, S. and Bressman, S.B. (1984) Should Levodopa Therapy for Parkinsonism Be Started Early or Late? Evidence against Early Treatment. Canadian Journal of Neurological Sciences, 11, 200-205. https://doi.org/10.1017/s0317167100046412 |
| [11] | Melamed, E. (1986) Initiation of Levodopa Therapy in Parkinsonian Patients Should Be Delayed until the Advanced Stages of the Disease. Archives of Neurology, 43, 402-405. https://doi.org/10.1001/archneur.1986.00520040080025 |
| [12] | Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A.H., Emre, M., et al. (2013) Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson’s Disease. Movement Disorders, 28, 1064-1071. https://doi.org/10.1002/mds.25364 |
| [13] | Howie, E.K., McVeigh, J.A. and Straker, L.M. (2016) Comparison of Compliance and Intervention Outcomes between Hip-and Wrist-Worn Accelerometers during a Randomized Crossover Trial of an Active Video Games Intervention in Children. Journal of Physical Activity and Health, 13, 964-969. https://doi.org/10.1123/jpah.2015-0470 |
| [14] | PD MED Collaborative Group (2014) Long-Term Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinson's Disease (PD MED): A Large, Open-Label, Pragmatic Randomized Trial. The Lancet, 384, 1196-1205. https://doi.org/10.1016/s0140-6736(14)60683-8 |
| [15] | Verschuur, C.V.M., Suwijn, S.R., Boel, J.A., Post, B., Bloem, B.R., van Hilten, J.J., et al. (2019) Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. New England Journal of Medicine, 380, 315-324. https://doi.org/10.1056/nejmoa1809983 |
| [16] | Bressman, S. and Saunders-Pullman, R. (2019) When to Start Levodopa Therapy for Parkinson’s Disease. New England Journal of Medicine, 380, 389-390. https://doi.org/10.1056/nejme1814611 |
| [17] | Yokochi, F. (2000) Pharmacological Treatment of Parkinsonian Tremor. Nihon Rinsho, 58, 2091-2095. |
| [18] | Ferreira, J.J., Katzenschlager, R., Bloem, B.R., Bonuccelli, U., Burn, D., Deuschl, G., et al. (2012) Summary of the Recommendations of the EFNS/MDS-ES Review on Therapeutic Management of Parkinson’s Disease. European Journal of Neurology, 20, 5-15. https://doi.org/10.1111/j.1468-1331.2012.03866.x |
| [19] | Muzerengi, S. and Clarke, C.E. (2015) Initial Drug Treatment in Parkinson’s Disease. British Medical Journal, 74, h4669. https://doi.org/10.1136/bmj.h4669 |
| [20] | Espay, A.J. and Lang, A.E. (2017) Common Myths in the Use of Levodopa in Parkinson Disease. JAMA Neurology, 74, 633-634. https://doi.org/10.1001/jamaneurol.2017.0348 |
| [21] | Ondo, W.G., Shinawi, L. and Moore, S. (2010) Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial. Movement Disorders, 25, 2724-2727. https://doi.org/10.1002/mds.23158 |
| [22] | Dhall, R. and Kreitzman, D.L. (2016) Advances in Levodopa Therapy for Parkinson Disease. Neurology, 86, S13-S24. https://doi.org/10.1212/wnl.0000000000002510 |
| [23] | Frequin, H.L., Schouten, J., Verschuur, C.V.M., Suwijn, S.R., Boel, J.A., Post, B., et al. (2023) Levodopa Response in Patients with Early Parkinson Disease. Neurology, 100, e367-e376. https://doi.org/10.1212/wnl.0000000000201448 |
| [24] | Chou, K.L., Stacy, M., Simuni, T., Miyasaki, J., Oertel, W.H., Sethi, K., et al. (2018) The Spectrum of “off” in Parkinson's Disease: What Have We Learned over 40 Years? Parkinsonism & Related Disorders, 51, 9-16. https://doi.org/10.1016/j.parkreldis.2018.02.001 |
| [25] | Kulisevsky, J., Oliveira, L. and Fox, S.H. (2018) Update in Therapeutic Strategies for Parkinson’s Disease. Current Opinion in Neurology, 31, 439-447. https://doi.org/10.1097/wco.0000000000000579 |
| [26] | Frampton, J.E. (2014) Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease. Drugs, 74, 2175-2190. https://doi.org/10.1007/s40265-014-0322-5 |
| [27] | Onofrj, M., Bonanni, L., De Angelis, M.V., Anzellotti, F., Ciccocioppo, F. and Thomas, A. (2009) Long Half-Life and Prolonged-Release Dopamine Receptor Agonists: A Review of Ropinirole Prolonged-Release Studies. Parkinsonism & Related Disorders, 15, S85-S92. https://doi.org/10.1016/s1353-8020(09)70842-9 |
| [28] | Schapira, A.H.V., Fox, S.H., Hauser, R.A., Jankovic, J., Jost, W.H., Kenney, C., et al. (2017) Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients with Parkinson Disease and Motor Fluctuations. JAMA Neurology, 74, Article 216. https://doi.org/10.1001/jamaneurol.2016.4467 |
| [29] | Fabbrini, G., Abbruzzese, G., Marconi, S. and Zappia, M. (2012) Selegiline. Clinical Neuropharmacology, 35, 134-140. https://doi.org/10.1097/wnf.0b013e318255838b |
| [30] | Larsen, J.P., Boas, J. and Erdal, J.E. (1999) Does Selegiline Modify the Progression of Early Parkinson’s Disease? Results from a Five-Year Study. European Journal of Neurology, 6, 539-547. https://doi.org/10.1046/j.1468-1331.1999.650539.x |
| [31] | Blanchet, P.J., Metman, L.V. and Chase, T.N. (2003) Renaissance of Amantadine in the Treatment of Parkinson’s Disease. Advances in Neurology, 91, 251-257. |
| [32] | Wu, J., Lu, A.D., Zhang, L.P., Zuo, Y.X. and Jia, Y.P. (2019) Study of Clinical Outcome and Prognosis in Pediatric Core Binding Factor-Acute Myeloid Leukemia. Chinese Journal of Hematology, 40, 52-57. |
| [33] | Khlebtovsky, A., Steiner, I., Treves, T. and Djaldetti, R. (2019) Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson’s Disease: An Open-Label Pilot Study. Clinical and Translational Science, 12, 586-590. https://doi.org/10.1111/cts.12684 |
| [34] | 曹开谊. 盐酸苯海索治疗帕金森病与帕金森综合征探究[J]. 中国处方药, 2015, 13(5): 84-85. |
